AC Immune’s (ACIU) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research report released on Friday,Benzinga reports. The firm currently has a $16.00 target price on the stock.

Separately, StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

AC Immune Stock Down 10.1 %

ACIU stock opened at $3.19 on Friday. AC Immune has a fifty-two week low of $2.25 and a fifty-two week high of $5.14. The stock has a market cap of $315.62 million, a PE ratio of -6.93 and a beta of 1.28. The firm’s 50-day simple moving average is $3.28 and its 200 day simple moving average is $3.49.

Institutional Trading of AC Immune

A number of institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. increased its position in shares of AC Immune by 294.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after purchasing an additional 328,312 shares during the period. Renaissance Technologies LLC lifted its holdings in AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after acquiring an additional 136,300 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of AC Immune during the 2nd quarter valued at about $218,000. Vanguard Capital Wealth Advisors acquired a new position in shares of AC Immune in the 2nd quarter worth approximately $56,000. Finally, Lazard Asset Management LLC acquired a new position in shares of AC Immune in the 1st quarter worth approximately $30,000. 51.36% of the stock is owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.